MedBioSphere
Articles Videos The Web  
    

The Immune Response Corporation

Selected Abstract

The Immune Response Corporation Initiates Phase II Study of REMUNE(R) With HIV-Infected Patients in Italy.
The Immune Response Corporation today announced the initiation of a Phase II clinical study designed to evaluate the use of REMUNE(R), an immune-based therapeutic vaccine, for treatment of HIV-infected patients who have not been treated previously with antiretroviral drugs. The study, which will ...
September 29, 2003; PR Newswire

Read the full article with a free-trial membership at HighBeam Research



Related Articles

1. The Immune Response Corporation to Present at Capital Growth Investor Forum.
2. The Immune Response Corporation Initiates a Preclinical Development Program with IR103, a New Vaccine Candidate for the Prevention and Treatment of HIV.
3. The Immune Response Corporation Licenses Hybridon's 2nd-Generation CpG DNA Adjuvant, AMPLIVAX(TM), for Use in Development of a Novel Vaccine for the Prevention and Treatment of HIV.
4. The Immune Response Corporation Presents Data at the International Congress of Immunology on HIV Product Candidate IR103.
5. The Immune Response Corporation Appoints David C. Mitchell as Executive Director, Regulatory Affairs.
6. The Immune Response Corporation to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference.
7. The Immune Response Corporation Announces A $5 Million Payment From Agouron Pharmaceuticals, Inc.
8. The Immune Response Corporation Announces a $5 Million Payment From Agouron Pharmaceuticals, Inc.
9. The Immune Response Corporation Issues Common Stock to Major Investor in Exchange for All Preferred Stock.
10. The Immune Response Corporation Signs a $15 Million Financing Agreement.